Synthesis of the organoarsenical antibiotic arsinothricin and derivatives thereof
申请人:Rosen Barry P.
公开号:US10934318B1
公开(公告)日:2021-03-02
The subject invention provides methods and procedures for synthesis and/or semi-synthesis of the novel antibiotic arsinothricin (AST) and derivatives. Arsinothricin (AST), a new broad-spectrum organoarsenical antibiotic, is a non-proteinogenic analog of glutamate that effectively inhibits glutamine synthetase. The subject invention provides chemical synthesis of an intermediate in the pathway of AST synthesis, hydroxyarsinothricin (AST-OH), which can be converted to AST by enzymatic methylation catalyzed by the ArsM As(III) S-adenosylmethionine methyltransferase. The methods provide a source of the novel antibiotic that will be required for future clinical trials. The subject invention also provides AST derivatives as a new class of antibiotics.
The use of chloroalkyldichloroarsines in hybrid ligand synthesis. The preparation of but-3-enylbis(3-dimethylarsinopropyl)arsine and 3-dimethylarsinopropylbis(but-3-enyl)arsine,and their reaction with nickel(II) salts to form pentacoordinate complexes. Novel nickel(II)—olefin bonds
作者:Fathy M. Ashmawy、F.Roger Benn、Charles A. McAuliffe、David G. Watson
DOI:10.1016/0022-328x(85)80069-3
日期:1985.5
nopropyl)arsine; n = 2, dasdol, 3-dimethylarsinopropylbis(but-3-enyl)arsine) by making use of the difference in reactivity between the ClC and AsCl bonds in the precursor Cl(CH2)mAsCl2 (m = 2,3) molecules. Thus, the triarsine obtained by reaction of 2-chloroethyldichloroarsine with the Grignard reagent of 3-chloropropyldimethylarsine yields 2-chloroethylbis(3-dimethylarsinopropyl)arsine, from which